Comment · Mon, September 16, 2019 · Natrium Health & Nootropics Depot
Neuralstem stock now worth ~1/100 of that before announcing NSI-189 MDD efficiency 'failure'
Original post in this thread
ranza · 8 points
I just checked and it totally shocked me.
It looks like the hopes have been high, but it really takes a long time to deliver the product.
Previously they've stated that:
> [ NSI-189] .. did not meet its primary efficacy endpoint of a statistically significant reduction in depression symptoms on the Montgomery-Asberg Depression Rating Scale (MADRS)
However, given an over one standard deviation improvement in memory with high confidence and other (quite big improvements) (wikipedia):
> Of particular note are improvements in memory (effect size Cohen's d = 1.12, p = 0.002), working memory (d = 0.81, p = 0.020), and executive functioning (d = 0.66, p = 0.048) as measured by the CogScreen computerized test.
I find it very weird that they didn't yet commercialize the product for any other (say, nootropic) purpose.
What do you think is happening?
What they were answering
ebowden · 1 points
Would you consider buying them when they went really low just to be able to use such a promising compound? Do you think this development might allow vendors like what Ceretropic was to start selling it without fear of their legal team being able to do anything?
u/MisterYouAreSoDumb · Natrium Health & Nootropics Depot
I am far from a larger pharma company with the resources to pick up where they failed. There would be no point in buying their IP without the ability to do something profitable with it. They will likely just die off and sell their IP piecemeal.